Health2Sync 智抗糖

🎉 謝謝 CommonWealth Magazine Group(天下雜誌群) 的報導！ We are covered by one of the leading business magazines in Taiwan- CommonWealth English 天下雜誌英文網! -- 慧康去年 10 月宣布，與賽諾菲共同開發的胰島素劑量調整軟體「#易速胰 」獲得台灣食藥署核發第二級醫療器材許可證，成為台灣第一個獲准的 #數位療法 ，追上國際趨勢。 共同創辦人暨執行長鄧居義 Ed Deng 解釋，因為開始打胰島素的前半年失敗率很高，#劑量抓不準 就造成血糖太高或太低，而數位療法的介入是為了幫助 #醫病合作 ，找到最適當的劑量，「#幫助病人度過最困難的前六個月 。」 拿到許可證是易速胰的第一步，除了臨床試驗，全台 12 家醫學中心也正收集 600 位患者的真實世界數據（RWD），要證明數位療法可以提升糖尿病患者的血糖控制成效。 -- The digital #basalinsulin #titration software co-developed with Sanofi has obtained the class-two medical device license issued by the Taiwan Food and Drug Administration, making it the first approved #digitaltherapeutics in Taiwan. "The high #failure #rate in the first six months of insulin initiation, where the dosage is inaccurate, leads to either too high or too low blood sugar levels. The intervention of digital therapeutics aims to assist the #collaboration between doctors and patients in finding the most appropriate dosage, helping patients overcome the most challenging process," said Co-founder and CEO Ed Deng in the interview. Getting the license is the first step. In addition to #clinicaltrials, 12 medical centers across Taiwan are also collecting real-world data (#RWD) from 600 patients to demonstrate that digital therapeutics can #improve glucose control in diabetes patients. 📰 閱讀全文：https://lnkd.in/gbKW7bjp

🎉 Thrilled to announce that Health2Sync 智抗糖 has been named one of Taiwan's #Top100 #Startups by the Taiwan Venture Capital Association ( TVCA )! This recognition is a testament to the hard work and dedication of our entire team. We're committed to developing innovative solutions that are making a positive impact on the healthcare industry, together with the government sector. Along with our fellow peers in the #biotechnology and #medicaldevice industry, Health2Sync is proud to be at the forefront of bringing Taiwan's cutting-edge healthcare technology to the world stage. We are confident that our solutions are empowering patients and healthcare providers to improve health outcomes and access care more efficiently. A huge thank you to the Taiwan startup ecosystem for its continued support. We're excited to see what the future holds for Health2Sync and the future of healthcare in Taiwan! 🇹🇼 Premier outlines hopes for Taiwan at Taiwan Venture Capital Summit: https://lnkd.in/gZtM9e8z 👉 Explore the full awarding list: https://lnkd.in/gbAHAR34 #Top100Startups #HealthcareInnovation #startup

📣 Join Health2Sync as a #Human #Resource Manager! Are you passionate about making a significant impact in the #healthcare and the #startup industry? We're seeking a talented HR Manager/HRBP to join our dynamic team in 🇯🇵 #Tokyo! 👋 Please join us if you're a native Japanese with motivation who: - Speaks good English or Mandarin - Have experience in #organizational #development and knowledge of #labor #laws - Possesses 3+ years of #recruitment experience - With excellent #interpersonal skills

We are excited to announce a groundbreaking partnership with Merdury Biopharmaceutical #水星生醫(6932) to accelerate #clinical #trials for oral #semaglutide! By leveraging Health2Sync's robust platform and extensive patient network in Taiwan, we’re empowering Merdury to gather critical data on the efficacy of their innovative #StackDose technology. This collaboration marks a significant milestone as Health2Sync becomes the first Taiwanese digital platform to support pharmaceutical companies conducting clinical trials. We’re proud to contribute to developing life-changing treatments for #chronicdiseases. 我們很高興能跟 #水星生醫 簽訂合作備忘錄，共同探索 #血糖管理 與 #體重控制藥品 之全球市場！ 未來雙方將利用 #智抗糖雲端照護平台 ，整合用戶的 #連續血糖監測資料 ，針對水星生醫研發出的 Semaglutide #口服錠劑 進行臨床試驗，此合作有助於確保臨床試驗成果與品質符合國際大廠要求，進一步幫助後續授權洽談。 水星生醫開發的 Semaglutide 口服錠劑於臨床前實驗得到令人振奮的結果。根據新聞指出，相對於原廠藥，水星生醫的口服錠劑不僅能夠縮短藥物達到血中藥物峰值的時間（Tmax）43％，還能使血中藥物總量提高 1.5 倍（AUC0-∞）。 👉 Read more in English: https://lnkd.in/gzGWHg94 👉 閱讀更多: https://lnkd.in/g9UaneQ4 #pharma #innovation #healthcare #digitalhealth

Great to connect with Prof. Shereen Abdelghaffar, Founder of EISPEDN and Director of Diabetes Club, at last week's event in Egypt! 🇪🇬 It was a fantastic opportunity to discuss the #challenges faced in diabetes care and explore how digital health solutions can revolutionize patient management. Our business development manager Hao-Wei Huang at Health2Sync, in partnership with Sanofi, presented innovative solutions aimed at #bridging #the #gap between healthcare professionals and patients. We also shared our vision for the future of diabetes care and outlined simple steps to implement digital solutions! #diabetes #digitalhealth #healthcare #Egypt #Sanofi #innovation

🇹🇼 Exciting news for a #healthier #Taiwan! Yesterday, Google Health announced the "#AI-on-#DM" project, a collaboration between Taiwan’s National Health Insurance Administration and Google Cloud to develop AI models for disease prediction and prevention of diabetes, Taiwan’s most common and top-spending chronic disease. “Health2Sync 智抗糖 has been one of Google Health's partners since 2019,” said Ed Deng, co-founder and CEO of Health2Sync, “we are thrilled to see more industry leaders contributing to a healthier, smarter #digital #health for Taiwan, and we are ready to be part of the team for a better #patient #care #experience!” 👉 Read in Mandarin: https://lnkd.in/gMg-ziFx 👉 Read in English: https://lnkd.in/g-jNGkPE

Last week, our co-founder and CEO Ed Deng was invited to speak at the BIO International Convention in San Diego, California! In the speech, Ed introduced Health2Sync's collaboration with #governments and #healthcare #providers in Asia to develop digital solutions for reducing #diabetes #complications and healthcare #costs. This includes remote care programs and #prediabetes #prevention efforts with industry leaders including Sanofi and Abbott. Looking ahead, Ed also believes that #AI will power #patientcentered digital health platforms within the next few years, and Health2Sync is excited to bring AI-driven solutions to patients around the world. 👉 Read the Mandarin coverage by Global Bio & Investment Monthly: https://lnkd.in/gBEpn-44

🇯🇵 Two weeks ago, our Co-founder and CEO Ed Deng joined the 67th Annual Meeting of the #JapanDiabetesSociety and shared the company's achievements in helping patients reach #satisfying #outcomes using personal health records #PHR. After using the Health2Sync App (#シンクヘルス),  - #74% of users take their #medication on time, - #80% continue #self #monitoring their blood glucose as instructed by their doctors. This improves #treatment #compliance and results in better outcomes. 🌸 👇 Please read the full Japanese story here! シンクヘルス株式会社

🇦🇺 Health2Sync will join this year's Digital Health Festival in Melbourne on 7 & 8 May! 📍 Please meet us at booth #441! We are excited to meet any possible global and local partners! 📩 DM our senior #businessdevelpment manager Steven Chen if you wish to reserve a chat during the exhibition! #diabetesmanagement #digitalcare #Taiwan #startups

🎧NEW #PODCAST ON AIR🎧 #wearehiringnow Earlier this month, our Co-founder and CEO Ed Deng was honored to share Health2Sync's philosophy and the motivational tales behind the years with Meet Global by Business Next Media! In this episode of Startup Island TAIWAN Podcast, Ed talks about: ☛ How a #technological #solution for #diabetes is developed? ☛ How did Ed acquire his #initial #users? ☛ The importance of healthcare-related partnerships and #realworldevidence ☛ The #innovation and opportunity in the #healthtech market 🤩 Enjoy listening! https://lnkd.in/gkdHM9-g 🙌 We are hiring for #onlinemarketing in #southkorea! Check the full JD here: https://lnkd.in/gGxJGzVY